Back
64
21
45
47
Day Range
$83.91
$83.91
52-Week Range
$83.91
$83.91
Volume
112
50D / 200D Avg
$83.91
/
$83.91
Prev Close
$83.91
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 17.4 | 0.4 |
| P/B | 3.7 | 2.9 |
| ROE % | 23.0 | 3.8 |
| Net Margin % | 14.0 | 3.9 |
| Rev Growth 5Y % | 17.3 | 10.0 |
| D/E | 0.6 | 0.2 |
Key Takeaways
Revenue grew 17.33% annually over 5 years — strong growth
Earnings grew 31.84% over the past year
ROE of 23.00% indicates high profitability
Generating 29.89M in free cash flow
PEG of 0.47 suggests growth is underpriced
Growth
Revenue Growth (5Y)
17.33%
Revenue (1Y)16.51%
Earnings (1Y)31.84%
FCF Growth (3Y)N/A
Quality
Return on Equity
23.00%
ROIC12.07%
Net Margin13.97%
Op. Margin16.80%
Safety
Debt / Equity
0.58
Current Ratio2.08
Interest Coverage16.87
Valuation
P/E Ratio
17.39
P/B Ratio3.66
EV/EBITDA16.44
Dividend Yield0.01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 16.51% | Revenue Growth (3Y) | 16.06% |
| Earnings Growth (1Y) | 31.84% | Earnings Growth (3Y) | 42.44% |
| Revenue Growth (5Y) | 17.33% | Earnings Growth (5Y) | 16.86% |
| Profitability | |||
| Revenue (TTM) | 688.06M | Net Income (TTM) | 96.09M |
| ROE | 23.00% | ROA | 10.48% |
| Gross Margin | 64.13% | Operating Margin | 16.80% |
| Net Margin | 13.97% | Free Cash Flow (TTM) | 29.89M |
| ROIC | 12.07% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.58 | Current Ratio | 2.08 |
| Interest Coverage | 16.87 | Dividend Yield | 0.01% |
| Valuation | |||
| P/E Ratio | 17.39 | P/B Ratio | 3.66 |
| P/S Ratio | 2.43 | PEG Ratio | 0.47 |
| EV/EBITDA | 16.44 | Dividend Yield | 0.01% |
| Market Cap | 1.67B | Enterprise Value | 1.90B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 688.06M | 590.58M | 510.78M | 437.12M | 363.13M |
| Net Income | 96.09M | 72.89M | 47.36M | 46.25M | 51.52M |
| EPS (Diluted) | 4.81 | 3.65 | 2.37 | 2.31 | 2.58 |
| Gross Profit | 441.27M | 399.44M | 347.85M | 305.26M | 261.25M |
| Operating Income | 115.62M | 90.83M | 74.44M | 61.46M | 58.78M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 916.65M | 792.18M | 695.87M | 584.49M | 489.27M |
| Total Liabilities | 460.57M | 412.51M | 365.83M | 309.83M | 262.87M |
| Shareholders' Equity | 456.08M | 379.66M | 330.04M | 274.66M | 226.40M |
| Total Debt | 262.48M | 241.21M | 201.98M | 170.25M | 132.66M |
| Cash & Equivalents | 33.18M | 31.59M | 20.79M | 32.26M | 20.40M |
| Current Assets | 449.54M | 395.38M | 348.47M | 283.66M | 228.03M |
| Current Liabilities | 216.47M | 157.55M | 149.42M | 89.06M | 136.56M |
Strategy Scores
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#78 of 326
#142 of 154
Custom
Balanced Risk
#83 of 148
Custom
Lower Risk
#58 of 136
Recent Activity
Entered
Growth Investing (Philip Fisher)
Mar 24, 2026
Entered
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Entered
Balanced Risk
Mar 24, 2026
Entered
Lower Risk
Mar 24, 2026